Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight ...
Weight loss drugs have surged in popularity, with millions turning to medications like Ozempic and Wegovy in hopes of shedding excess weight and managing diabetes. These drugs, classified ...
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback